Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema

Plasma-derived C1 esterase inhibitor pharmacokinetics and safety in patients with hereditary angioedema

Background: Over 40 years of use demonstrates that complement 1 esterase inhibitor (C1-INH) concentrate is effective and well tolerated for acute edema attacks and prophylaxis in patients with hereditary angioedema. OCTA-C1-INH is a new stable, virus-inactivated, nanofiltrated concentrate of C1-INH...

Full description

Bibliographic Details
Main Authors: Inmaculada Martinez-Saguer, MD, PhD, Konrad Bork, MD, Tatiana Latysheva, MD, PhD, Liudmyla Zabrodska, PhD, Valentyna Chopyak, MD, PhD, Natalia Nenasheva, MD, Areg Totolyan, MD, PhD, Vitaliy Krivenchuk, PhD
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Complement 1 esterase inhibitor
hereditary angioedema
open-label
pharmacokinetic
plasma-derived
safety
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829323001030

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323001030

Similar Items